AtriCure, Inc. vs Johnson & Johnson — Stock Comparison
Q·Score Breakdown
6.7
Neutral
Overall
7.1
Bullish
Quality
Health
Growth
Valuation
Sentiment
ATRC
Clean balance sheet with low leverage (0.2× debt-to-equity).
⚠ currently unprofitable (-2% margin).
JNJ
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
BUY
Target $46.75 (+61.1%)
8 analysts
BUY
Target $252.42 (+11.1%)
24 analysts
Fundamentals
ATRC
JNJ
—
Trailing P/E
26.3×
78.5×
Forward P/E
17.9×
-2.1%
Profit Margin
21.8%
75.0%
Gross Margin
68.0%
-2.4%
ROE
26.4%
13.1%
Revenue Growth
9.9%
—
Earnings Growth
-52.9%
1.43
Beta
0.33
—
Price / Book
—
$1.5B
Market Cap
$546.9B
$27 – $43
52-Week Range
$146 – $252
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →